No Data
No Data
No Data
Rekindle the money-making effect? Inventory and outlook of Hong Kong stock IPOs
Along with expectations of valuation restoration, market sentiment is expected to gradually pick up, and new share purchases may become popular again.
Ma Long Dental Clinic, from Jiaxing, Zhejiang, went public in Hong Kong and received a “Notice of Filing” from the China Securities Regulatory Commission
According to the new overseas listing and filing regulations for domestic companies that came into effect on March 31, 2023, companies chose to list H-shares in Hong Kong. The original path of big and small is a thing of the past. Companies listed overseas can directly submit a prospectus, and the roadmap will be replaced by a “filing notice”.
IPO News丨Ma Long Medical's Hong Kong Stock Listing and “Full Circulation” Filed to Issue No More Than 253 Million Shares
On January 2, the China Securities Regulatory Commission issued a filing notice on the overseas issuance and “full circulation” of shares listed overseas and unlisted domestic shares of Ma Long Medical Management (Zhejiang) Co., Ltd.
Nine companies, including SF Express, Aggregate Data, Jinyuan Hydrogen Energy, Weisheng Pharmaceutical, Shenghe Biotech, Egg, and Baide Medical, are planning to be listed in Hong Kong/US to file supplementary material requirements (feedback)
Requirements for supplementary materials for overseas issuance and listing registration (September 15, 2023 to September 21, 2023)
IPO News | Ma Long Dental's proposed Hong Kong stock IPO, China Securities Regulatory Commission requires explanation of changes in equity and major asset acquisitions
On September 22, the China Securities Regulatory Commission issued a public announcement on the requirements for supplementary materials for overseas issuance and listing registration (September 15, 2023 to September 21, 2023)
IPO Preview|Ma Long Dental's IPO in Hong Kong: Each dentist earns an average income of 2.4 million yuan
Focusing on the fundamentals of Umataki Dental Clinic, it is easy to see that “steady revenue growth and poor profit conditions” is a shadow that pervades the hearts of many investors.
No Data
No Data